{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.9","upperLimit":"45.5","value":"2"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.9","upperLimit":"45.5","value":"9"}]}],"title":"Disease progression"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.9","upperLimit":"45.5","value":"2"}]}],"title":"Symptomatic deterioration"}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Tumor response was assessed every eight weeks per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions as assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Stable disease (SD) was defined as having no evidence of response (CR or PR) as best response to therapy, and no evidence of disease progression (appearance of new lesions or \\>/= 30% increase in target lesions) at 8 weeks.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive FR901228 (depsipeptide) IV at 13 mg/m\\^2 over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nromidepsin: Given IV","id":"OG000","title":"Treatment (Romidepsin)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Disease Control (i.e., Achievement of Complete Response, Partial Response, or Stable Disease)","type":"PRIMARY","unitOfMeasure":"participants"}